Zhang JJH, et al. - In this pilot study, researchers investigated if HSD3B1 homozygous variant genotype was related to elevated 3β-hydroxysteroid dehydrogenase (3βHSD1) immunoreactivity vs wild-type (WT) genotype. From 30 patients with prostate cancer (10 WT, 10 heterozygous, and 10 homozygous variant), prostatectomy tissues were extracted, from which HSD3B1 genotypes were obtained. They carried out immunostaining for 3βHSD1 using a validated mouse monoclonal antibody. Findings revealed that based on the HSD3B1 genotype, tissue expression of 3βHSD1 varied, with the most robust 3βHSD1 expression demonstrated by homozygous variant HSD3B1 (1245A>C) specimen vs heterozygous and WT prostates. In predicting aggressive disease, 3βHSD1 appeared to have potential as a prostate biomarker.